DR. VARSHA DANDAVATE MD
Prescription History 1710180039
Internal Medicine - Infectious Disease in Norfolk, VA


Quality Rating: 95.11 out of 100 score

NPI Status: Active since June 06, 2007

Contact Information

301 RIVERVIEW AVE STE 710
NORFOLK, VA
ZIP 23510
Phone: (757) 252-9040

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. VARSHA DANDAVATE MD, an active Infectious Disease specialist practicing in Norfolk, VA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 104 documented patient claims. Among these therapy options, the most frequently utilized medication is Ampicillin-Sulbactam, which accounts for 19 claims alone.

Medication Index


Ampicillin-Sulbactam

Generic Formulation: Ampicillin Sod/Sulbactam SodSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 61
VA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.3
Peer Average Days Supply48
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,886.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$151.90

State Avg Cost Per Claim

$108.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a wide variety of bacterial infections. It is known as a penicillin-type antibiotic. It works by stopping the growth of bacteria.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
VA State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills77.2
Peer Average Days Supply2,313
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.1% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $46,488.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,226.19

State Avg Cost Per Claim

$3,996.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefepime Hcl

Generic Formulation: Cefepime HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 96
VA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.0
Peer Average Days Supply133
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,906.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$152.98

State Avg Cost Per Claim

$202.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Therapeutic Applications

Cefepime is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria.

Efavirenz-Emtric-Tenofov Disop

Generic Formulation: Efavirenz/Emtricit/Tenofovr DfSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
VA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply570
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,213.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$785.65

State Avg Cost Per Claim

$1,208.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 different medications: efavirenz, emtricitabine, and tenofovir. It is used alone or with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Efavirenz belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Emtricitabine and tenofovir belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Efavirenz/emtricitabine/tenofovir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Isentress

Generic Formulation: Raltegravir PotassiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
VA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply732
Conservative Utilization

This provider writes prescriptions for this formulation 43.5% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,535.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,041.16

State Avg Cost Per Claim

$2,041.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

Therapeutic Applications

Raltegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Raltegravir is known as an integrase inhibitor. It blocks the virus from growing and infecting more cells. Raltegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Triumeq

Generic Formulation: Abacavir/Dolutegravir/LamivudiSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
VA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills41.4
Peer Average Days Supply1,240
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.2% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44,661.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,721.77

State Avg Cost Per Claim

$3,722.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Abacavir and lamivudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 83
VA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply67
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,438.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$84.60

State Avg Cost Per Claim

$87.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. VARSHA DANDAVATE MD provides transparency into local medical care patterns within Norfolk, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.